- Koru Medical Systems ( NASDAQ: KRMD ) said it signed an agreement with a pharmaceutical manufacturer of subcutaneous immunoglobulin therapy (SCIg) to develop and seek regulatory approval of the company's Freedom Infusion System with an SCIg prefilled syringe.
- Terms of the agreement were not disclosed.
- "As KORU Medical looks to simplify subcutaneous drug delivery for patients in the home, we are excited to partner with another major pharmaceutical company to further innovate our Freedom Infusion System for use with their prefilled syringes," said Koru's President and CEO Linda Tharby.
- The agreement provides for Koru to develop an adaptation to its Freedom Infusion System to enable an SCIg prefilled syringe to be usable by patients globally and seek regulatory authorization for adaptation.
For further details see:
Koru inks pact to develop Freedom infusion system with prefilled syringe